CALR and neoplasm: In comparison to the control group, calreticulin (CRT) and high mobility group box protein B1(HMGB1) expression were significantly higher in tumor tissue after combined treatment with Cu-LCP/DSF NPs and anti-PD-1 (Fig. 7F).